Recent Updates
01
Amira Pharmaceuticals Appoints First Vice President of Development
November 1st, 2007
Amira Pharmaceuticals, Inc
San Diego, CA – November 1, 2007- Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory disease linked to the eicosanoid pathway, today announced the appointment of Isabelle Raizon-Ounis, M.D., as vice president of development. (more…)
01
Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
November 1st, 2007
Amira Pharmaceuticals, Inc
San Diego, CA – November 1, 20072007 — Amira Pharmaceuticals, Inc. announced completion of the company’s Phase 1 clinical trial of AM103, Amira’s internally discovered oral drug candidate for the treatment of inflammatory diseases linked to the leukotriene pathway. Amira also announced the start of a Phase 1 trial for AM803, a second oral drug candidate that targets the same inflammatory response. (more…)
21
Chasing Memory – Part 1 of 4 One man’s epic quest for understanding
September 21st, 2007
Gary Lynch has spent decades trying to understand how the brain processes new information so that we can recall it later. (more…)
21
Chasing Memory – Part 2 of 4 Trials, and a series of errors, in the brain lab
September 21st, 2007
Gary Lynch’s UC Irvine research team struggles to understand how memories are made. It is crucial to treating age-related declines. (more…)
21
Chasing Memory – Part 3 of 4 Breakthroughs, and new crises, in the lab
September 21st, 2007
Gary Lynch and his UC Irvine lab team begin to piece together the story of human memory. Then his own brain becomes the focus. (more…)
21
Chasing Memory – Part 4 of 4 Success and rejection
September 21st, 2007
Gary Lynch expects his brain lab’s work to bring ‘all the tribes of neuroscience to the same campfire.’ Instead, he meets resistance. (more…)
20
Hardware Can Be Open, Too Open Ideas to Open Source: Hacking Hardware
September 20th, 2007
Matt Hartley
With open source software becoming a household name, another open source movement that may one day see some fanfare is already taking shape. Open source hardware, which I once thought to be little more than a pipe dream left over from a bygone era, is proving to be a dream that it is very much alive and growing. (more…)
18
Kaltura Wins Spot as 40th Company at TechCrunch40
September 18th, 2007
Mark Hendrickson
Brooklyn-based Kaltura has earned the honor to present as the 40th company in this year’s TechCrunch40 conference, beating next generation forums provider Tangler by a handful of votes. (more…)
14
New Heights: Take your business higher with funding from one of these top VCs
September 14th, 2007
Entrepreneur Magazine
July 2007
Great news for entrepreneurs last year: Venture capitalists invested $25.5 billion in 3,416 deals in 2006–a 10 percent increase in deal volume and a 12 percent increase in dollar values from 2005, according to the “MoneyTree Report” by PricewaterhouseCoopers and the National Venture Capital Association, based on data from Thomson Financial. And what’s even more encouraging is that the year marked the highest level of investment since 2001.
16
Lahaina biotech company gets $3M in venture capital
August 16th, 2007
Advertiser Staff
The Honolulu Advertiser
InCode BioPharmaceutics Inc. in Lahaina received $3 million in venture capital from Avalon Ventures during the second quarter, according to the PriceWaterhouseCoopers Moneytree survey. The company is developing therapeutic compounds to treat autoimmune disorders.
Hawaii Bioenergy LLC in Honolulu received $200,000 from Finistere Partners, according to the survey. The company is researching crops for renewable biofuel production.
30
Amira Pharmaceuticals Announces Appointment of First Chief Executive Officer
July 30th, 2007
San Diego, CA – Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory disease linked to the eicosanoid pathway, today announced that the company has appointed Robert F. Baltera, Jr., as the company’s first chief executive officer, effective immediately. (more…)
16
Amira Pharmaceuticals Announces Positive Initial Data from a Phase 1 Study of AM103, A Novel Product Candidate for the Treatment of Respiratory and Cardiovascular Disease
July 16th, 2007
San Diego, CA – Amira Pharmaceuticals, a small molecule pharmaceutical company focused on the discovery and development of compounds to treat inflammatory diseases linked to the eicosanoid pathway, today announced initial, positive data from a Phase 1 clinical trial of AM103, the company’s lead compound. The early, interim results demonstrate that a single dose of AM103 achieves highly significant inhibition of leukotriene synthesis. (more…)
16
Super-buff cattle may hold key to treating muscular diseases
July 16th, 2007
Cambridge biotech trying to mimic breed’s genetics (more…)
09
Biovex Raises $22 Million In First Close Of Series E Financing
July 9th, 2007
Woburn, MA – BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it had raised $22m in the first close of a series E private financing. (more…)
06
Kinomics: The New Star
July 6th, 2007
Drug Discovery and Development
By James Netterwald, PhD, MT (ASCP)
Kinases are one of the most important classes of protein in cells. They play a role in cellular signaling, regulating everything from cell growth to inflammation. But, more importantly, when their function goes awry, kinases have been implicated in certain human cancers. Because of this role in cancer, kinases have been on the priority list that drug companies draw up while looking for new drug targets for years. (more…)
12
Robert J. Zollars Named Chairman And Ceo Of Vocera Communications
June 12th, 2007
By Jan Rasmussen
CUPERTINO, Calif. (June 12, 2007) – Vocera Communications, Inc., developers of the Vocera Communications System, the only wearable, hands-free instant voice communication system available on the market, today appointed Robert J. Zollars as Chairman and CEO of the company.
08
Intercasting Corp. Secures $12 Million in Series B Venture Funding
May 8th, 2007
Venrock, Avalon Ventures and Masthead Venture Partners Support Expansion of Mobile Social Networking Through the ANTHEM Platform and Rabble (more…)
23
Amira Pharmaceuticals Raises $25 Million
March 23rd, 2007
Funding Led by Avalon Ventures, Prospect Venture Partners and Versant Ventures (more…)